Observational studyEuropean radiology2017
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Observational study in European radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Comparative Efficacy and Safety of Transarterial Therapies for Unresectable Neuroendocrine Liver Metastases: A Systematic Review.Cardiovascular and interventional radiology · 2026Pooled it
- Systematic review of multimodal management strategies for Insulinoma-Induced hypoglycaemia: current evidence and future directions.Endocrine · 2026Pooled it
- Yttrium-90 Selective Internal Radiation Therapy for Neuroendocrine Liver Metastases: An Institutional Case Series, Updated Systematic Review, and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Long‑term survival after comprehensive treatment in a patient with advanced neuroendocrine neoplasm of the pancreas: A case report.Oncology letters · 2025Article
- Gastroenteropancreatic neuroendocrine neoplasms in children and adults: a comparative review.Frontiers in endocrinology · 2025Review
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?Seminars in interventional radiology · 2024Review
- New frontiers in radioembolization.Therapeutic advances in medical oncology · 2024Review
- Transcatheter arterial embolization in patients with neuroendocrine neoplasms related to liver metastasis with different blood supplies.Cancer medicine · 2023Article
- Article
- Review
- Review
- Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis.Cardiovascular and interventional radiology · 2022Article
- Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.Clinical imaging · 2022Article
- Article
- Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.Cancers · 2022Review
- Article
- Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures.Cancers · 2021Review
- CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation.Cardiovascular and interventional radiology · 2021Article
- Radioembolization of Secondary Hepatic Malignancies.Seminars in interventional radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
objectivesTo compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM).
methodsThis retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014. Radiologic response to therapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) and World Health Organization (WHO) criteria using periprocedural MR imaging. Survival analysis included propensity score analysis (PSA), median overall survival (MOS), hepatic progression-free survival, Kaplan-Meier using log-rank test and the uni- and multivariate Cox proportional hazards model (MVA).
resultsMOS of the entire study population was 28.8 months. As for cTACE, DEB-TACE and Y90, MOS was 33.8 months, 21.7 months and 23.6 months, respectively. According to the MVA, cTACE demonstrated a significantly longer MOS as compared to DEB-TACE (p <.01) or Y90 (p = .02). The 5-year survival rate after initial cTACE, DEB-TACE and Y90 was 28.2%, 10.3% and 18.5%, respectively.
conclusionsUpon PSA, our study suggests significant survival benefits for patients treated with cTACE as compared to DEB-TACE and Y90. This data supports the therapeutic decision for cTACE as the primary intra-arterial therapy option in patients with unresectable NELM until proven otherwise. KEY POINTS: • cTACE achieved a significantly longer overall survival in patients with unresectable NELM. • Patients treated with cTACE showed a prolonged hepatic progression-free survival. • cTACE, DEB-TACE and Y90 radioembolisation demonstrated comparable safety and toxicity profiles. • Age >70 years, extrahepatic metastases and tumour burden >50% were identified as negative predictors. • Propensity score analysis suggests the superiority of cTACE over DEB-TACE and Y90.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.